About 7

CardioBrief is a one-stop source for  new and important information of interest to cardiologists and other cardiovascular healthcare professionals. CardioBrief is written by Larry Husten, the editor of TheHeart.Org from its inception in 1999 until December 2008. Following the purchase of TheHeart.Org by WebMD in 2005 he became the editorial director of WebMD professional news, encompassing TheHeart.Org and Medscape Medical News. Prior to joining TheHeart.Org he was a freelance medical journalist who wrote for the Lancet, the New York Times, Discover, and many other medical and computer publications. In 1994-1995 he was a Knight Science Journalism Fellow at MIT. He received a PHD in English from the State University of New York at Buffalo and drove a taxicab in New York City before embarking on a career in medical journalism.

In January 2010, Husten became a consulting editor and news director at CardioExchange, an online cardiology community published by the New England Journal of Medicine.

CardioBrief is entirely noncommercial, with no financial ties or relationships with industry.

Email: lhusten@mac.com.

Click here to follow CardioBrief on Twitter





  1. Pingback: Conference walks back description of partnership with health website : Covering Health

  2. Pingback: FDA says reporters can’t interview anyone before its embargo lifts « Embargo Watch

  3. I think its embarrasing that the ACC/AHA included newbies like Multaq (dronedarone) and Pradaxa (dabigatran) in their AF recommendations so quickly and shamelessly. Now we wait to see them sheepishly back track when the “non-inferiority” becomes me-too-given-too-prematurely.

    I am sure you’ve read the ProPublica piece on the incestuous ties Heart Rhythm Society has with drug and device manufacturers.

    Some one has to tell these guys that we know what time it is.

    Congrats Mr. Husten great coverage quite unlike what one gets in the Industry sympathetic specialist medical publications.
    I hope you keep it up and dont get bought over.

    Wilbur Larch MD, FACC

    • On the spot Dr Wilbur, I think Medical media channel shouldn’t be tied to device / manufacturer.

      However, what made you say FDA approval was premature? The RCT evidences are there isn’t.

      Beni Rusani MBChB

What do you think?

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s